168 related articles for article (PubMed ID: 38310626)
1. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
Pelewicz K; Miśkiewicz P
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38310626
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.
Pelewicz K; Szewczyk S; Miśkiewicz P
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050327
[TBL] [Abstract][Full Text] [Related]
3. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
4. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
6. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
7. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
8. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.
Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P
Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547
[TBL] [Abstract][Full Text] [Related]
9. Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
Rymuza J; Gutowska K; Kurpios-Piec D; Struga M; Miśkiewicz P
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078937
[TBL] [Abstract][Full Text] [Related]
10. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
11. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
13. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
14. Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy.
Walasik-Szemplińska D; Kamiński G; Sudoł-Szopińska I
Thyroid Res; 2019; 12():13. PubMed ID: 31890036
[TBL] [Abstract][Full Text] [Related]
15. Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
Eguchi H; Tani J; Hirao S; Tsuruta M; Tokubuchi I; Yamada K; Kasaoka M; Teshima Y; Kakuma T; Hiromatsu Y
Int J Endocrinol; 2015; 2015():835979. PubMed ID: 26221141
[TBL] [Abstract][Full Text] [Related]
16. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome.
Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P
J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161
[TBL] [Abstract][Full Text] [Related]
17. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
18. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]